PATENT CLAIM ANALYSIS

Application Number: 16167835
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["544", "265000"]

Abstract:
To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.

Claim (Index 16):
The method according to  claim 12 , wherein 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof is administered before the at least one additional anticancer agent.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 97.0
- Lexical Diversity: 1.66667
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15208998', '14666496', '15648941', '15158993', '15653614']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7972176558436113
- 35 USC 102 Novelty (BERT): 0.6644298373492231
- Combined Prediction Score: 0.7839388739941725
- Mean Citation Score: 483.513954
- Max Citation Score: 657.9763
- Similarity Product: 625.825176784158

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test